Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jeong Won | - |
dc.contributor.author | Jun, Sun-Young | - |
dc.contributor.author | Ylaya, Kris | - |
dc.contributor.author | Chang, Hee-Kyung | - |
dc.contributor.author | Oh, Young-Ha | - |
dc.contributor.author | Hong, Seung-Mo | - |
dc.contributor.author | Chung, Joon-Yong | - |
dc.contributor.author | Hewitt, Stephen M. | - |
dc.date.accessioned | 2022-07-07T02:38:43Z | - |
dc.date.available | 2022-07-07T02:38:43Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142600 | - |
dc.description.abstract | Objective: Hairy and enhancer of split-1 (HES-1), which is a downstream target of the Notch signaling pathway, has been linked to KRAS mutations. HES-1 has been proposed as harboring oncogenic activity in colorectal cancer but has not been investigated in adenocarcinoma of the small intestine, where the drivers of oncogenesis are not as well-understood. Materials and Methods: To investigate the clinicopathologic and prognostic implications of HES-1, HES-1 immunohistochemical expression was analyzed in digital images along with clinicopathological variables, including survival and KRAS genotype, in 185 small intestinal adenocarcinomas. Results: The loss of HES-1 expression (HES-1Loss) was observed in 38.4% (71/185) of the patients, and was associated with higher pT category (P = 0.018), pancreatic invasion (P = 0.005), high grade (P = 0.043), and non-tubular histology (P = 0.004). Specifically, in tumors with mutant KRAS (KRASMT), HES-1Loss was related to proximal location (P = 0.024), high T and N categories (P = 0.005 and 0.047, respectively), and pancreatic invasion (P = 0.004). Patients with HES-1Loss showed worse overall survival compared to those with intact HES-1 (HES-1Intact) (P = 0.013). Patients with HES-1Loss/KRASMT (median, 17.3 months) had significantly worse outcomes than those with HES-1Intact/KRASWT (39.9 months), HES-1Intact/KRASMT (47.6 month), and HES-1Loss/KRASWT (36.2 months; P = 0.010). By multivariate analysis, HES-1Loss (hazard ratio = 1.55, 95% confidence interval (CI), 1.07–2.26; P = 0.022) remained an independent prognostic factor. Conclusion: HES-1expression can be used as a potential prognostic marker and may aid in the management of patients with small intestinal adenocarcinomas. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Young-Ha | - |
dc.identifier.doi | 10.3389/fonc.2020.01427 | - |
dc.identifier.scopusid | 2-s2.0-85090201302 | - |
dc.identifier.wosid | 000567860100001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.10, pp.1 - 10 | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | KRAS MUTATION | - |
dc.subject.keywordPlus | CELL-PROLIFERATION | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | NOTCH | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | BRAF | - |
dc.subject.keywordAuthor | HES-1 | - |
dc.subject.keywordAuthor | KRAS | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | small intestine | - |
dc.subject.keywordAuthor | adenocarcinoma | - |
dc.identifier.url | https://www.frontiersin.org/articles/10.3389/fonc.2020.01427/full | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.